L'exil de Jan Cep (contribution à l'histoire de la littérature tchèque moderne)

L écrivain tchèque Jan Cep (1902-1974), qui compta au nombre des médiateurs importants des rapports culturels franco-tchèques dans l entre-deux-guerres, fut, à la suite du Coup de Prague en 1948, contraint à quitter son pays. Ami et traducteur de Pourrat et de Bernanos, il choisit naturellement la France comme patrie d adoption. L exil parisien s avère pour Cep une rude épreuve existentielle. Conditions matérielles dures, déracinement linguistique, manque d écho favorable pour son oeuvre, tout cela fait que Cep vit en marge de la vie littéraire française. Il s engage d autant plus dans diverses structures de l émigration tchèque, notamment dans la rédaction tchécoslovaque de Radio Free Europe où il déploie son art de l essai dans des méditations imprégnées d humanisme chrétien. L essai autobiographique Ma soeur l angoisse que Cep écrivit directement en français dans les années 1960, représente la somme de sa vie et de sa penséeThe Czech writer Jan Cep (1902-1974), one of important mediators of French-Czech cultural relations between the two World Wars, was forced to emigrate after the Communist coup in 1948. As Cep was the friend and translator of Pourrat and Bernanos, he naturally chose France as his adoptive homeland. Nevertheless, exile in Paris turned into a harsh existential ordeal for Cep. Difficult material conditions, linguistic disunity, and the fact that his writing was not accepted by a new audience made Cep an outsider in a French literary life. This status led to his increased involvement in the Czech émigré community, especially work on the Czechoslovak editorial staff of Radio Free Europe, where he developed his essay style in meditations infused with Christian humanism. The autobiographical essay My Sister Anxiety, written in French in the 1960s, repesents a summary of Cep s life and ideasPARIS-EST-Université (770839901) / SudocPARIS12-Bib. électronique (940280011) / SudocSudocFranceF

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible

COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

: Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P&lt;0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible